FDA approves first in class targeted therapy for metastatic pancreatic cancer
The FDA has granted accelerated approval to Rasonque, a new targeted therapy for patients with metastatic pancreatic adenocarcinoma. The drug acts as a RAS inhibitor, offering a new treatment option for a historically difficult-to-treat cancer.
Why it matters
This approval provides a significant medical advancement for a cancer type with historically poor survival rates and limited treatment options.
The U.S. Food and Drug Administration today approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule.
The report is a factual summary of a regulatory announcement regarding medical approval.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in